Europe
Satellite Symposium will focus on the continued need for innovative drugs in ulcerative colitis, the novel mechanism of action of ABX464 as well as clinical data from the Phase 2a induction and maintenance studies
In its annual report, Novartis said it has stopped working on the years-long project and will record a $442 million impairment charge as a result.
No treatments are currently approved for the disease.
Syndivia receives the exclusive license from SATT Conectus to DARx technology, which allows them to generate monodisperse 1-to-1 conjugates starting from off the shelf protein substrates.
The Company and its wholly owned subsidiary, Motif BioSciences Inc., have entered into a loan Amendment and Release agreement with Hercules Capital Inc., the senior secured lender to Motif Inc, regarding certain actions which fully satisfy the conditions attached to the Company’s previously announced agreement in principle with Hercules
CYNBIOME receives funding under Investments for the Future Program (PiA), supplemented by €3M ($3.3M) of Cynbiose’s own funds
Digital Value-Added Medicines, waste management and the use of blockchain identified as key trends for the upcoming year
Analysis finds that highly innovative drugs took longer to reach NHS patients than more conventional treatments
Pharma companies from across the globe provide updates on their pipelines and business.
China’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.
PRESS RELEASES